| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.4M | 0.00% | 164.00K | +7.5% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TENX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Doogan DeclanDirector | Purchase at price 1.92 per share. | 53K | $101.76K |
| Sep 14, 2026 | Giordano Christopher ThomasChief Executive Officer | Purchase at price 1.82 - 1.88 per share. | 10.8K | $20.09K |
| Sep 10, 2026 | Staab Thomas R IiChief Financial Officer | Purchase at price 1.94 per share. | 5.7K | $10.98K |
| Sep 2, 2026 | Adar1 Capital Management LlcBeneficial Owner of more than 10% of a Class of Security | Purchase at price 1.78 per share. | 900K | $1.60M |
| Sep 1, 2026 | Adar1 Capital Management LlcBeneficial Owner of more than 10% of a Class of Security | Purchase at price 1.79 - 1.80 per share. | 770.3K | $1.38M |
| Aug 23, 2026 | Adar1 Capital Management LlcBeneficial Owner of more than 10% of a Class of Security | Purchase at price 1.75 - 1.78 per share. | 1.03M | $1.81M |
| Jul 12, 2026 | Giordano Christopher ThomasChief Executive Officer | Conversion of Exercise of derivative security at price 3.55 - 5.94 per share. | 8.7K | $51.27K |
| May 10, 2026 | Staab Thomas R IiChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Jan 29, 2026 | Mcgauley Thomas AChief Financial Officer | Conversion of Exercise of derivative security at price 12.51 per share. | 50K | $625.50K |
| Dec 8, 2025 | Rich StuartOfficer and Director | Purchase at price 10.10 - 10.22 per share. | 5K | $50.79K |
| Dec 3, 2025 | Rich StuartOfficer and Director | Purchase at price 9.01 - 9.20 per share. | 5K | $45.62K |
| Nov 19, 2025 | Giordano Christopher ThomasChief Executive Officer | Purchase at price 7.51 - 7.75 per share. | 2.6K | $20.00K |
| Nov 17, 2025 | Almenoff June SherieDirector | Purchase at price 7.15 - 7.52 per share. | 2K | $14.95K |
| Nov 17, 2025 | Almenoff June SherieDirector | Purchase at price 7.15 - 7.52 per share. | 2K | $14.95K |
| Nov 16, 2025 | Mcgauley Thomas AChief Financial Officer | Purchase at price 7.23 - 7.35 per share. | 8K | $58.16K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.6 | -4.1 | 33.2 | -18.0 | -9.5 | 22.6 | -5.8 | -86.6 | 2.7 | -13.3 | −86.6% | ||
| 2025 | -3.1 | -0.5 | 9.7 | -12.1 | 5.0 | -4.8 | 8.3 | -4.0 | 27.0 | -3.5 | 28.5 | 29.3 | +96.9% |
| 2024 | -40.5 | -64.9 | -7.6 | -8.0 | -11.3 | -12.9 | 12.8 | 17.4 | -13.3 | 26.9 | 22.1 | 15.5 | −71.9% |
| 2023 | -4.5 | -67.9 | -31.6 | -30.5 | 12.4 | -17.4 | 5.0 | 11.1 | -14.6 | -37.8 | 87.6 | -21.2 | −87.6% |
| 2022 | -37.5 | -9.5 | 37.8 | -10.2 | -9.2 | -54.5 | -12.0 | -9.5 | -28.9 | -22.4 | 12.1 | -25.0 | −89.3% |
| 2021 | 23.7 | -6.5 | -11.6 | 0.0 | 2.6 | 6.7 | -16.8 | -8.1 | 11.3 | -14.1 | -15.8 | -18.8 | −44.1% |
| 2020 | -5.0 | -11.9 | -51.5 | 14.5 | 119.8 | -37.2 | 47.0 | 7.5 | 7.7 | -31.2 | 1.9 | 72.2 | +31.9% |
| 2019 | -3.3 | 3.4 | 66.9 | -14.9 | -23.3 | 4.5 | -5.1 | -7.6 | -0.8 | 8.3 | -5.4 | 14.6 | +16.5% |
| 2018 | -33.3 | -29.1 | 17.9 | 13.9 | -2.1 | 3.4 | -0.2 | -12.2 | -4.9 | -5.1 | -56.7 | -44.0 | −87.7% |
| 2017 | -76.4 | 58.3 | -22.7 | -5.9 | -4.7 | 46.3 | -33.7 | -30.6 | 6.2 | 19.1 | -4.7 | 19.5 | −74.9% |
| 2016 | -19.8 | -13.7 | -9.7 | 32.7 | -7.4 | 1.6 | -3.9 | -5.3 | -0.6 | -31.3 | 21.4 | 1.0 | −40.5% |
| 2015 | -11.5 | -7.4 | 3.5 | 4.9 | 6.7 | 1.1 | 0.5 | -10.8 | -9.4 | 6.0 | 1.9 | 1.2 | −14.6% |
| 2014 | 37.3 | 4.7 | -14.2 | -12.1 | -3.9 | -13.0 | -9.3 | 13.5 | -6.4 | 0.8 | -5.3 | 2.4 | −14.7% |
| 2013 | 6.2 | -58.9 | -11.0 | 0.0 | -25.4 | -20.6 | -46.3 | -17.0 | 11.4 | 106.8 | 106.3 | -28.2 | −65.1% |
| 2012 | 39.9 | 34.5 | -12.6 | -24.3 | 12.9 | -21.9 | -31.8 | -17.8 | -31.8 | 75.0 | -34.3 | -6.7 | −55.0% |
| 2011 | 6.8 | -5.9 | -4.7 | -3.8 | 11.9 | 50.9 | -17.4 | -7.7 | -8.3 | 1.0 | -9.5 | -25.1 | −25.5% |
| 2010 | -4.2 | -11.0 | -2.0 | 0.0 | -40.6 | -2.7 | -5.2 | 10.9 | -16.8 | -16.6 | 1.9 | -10.7 | −67.9% |
| 2009 | 27.1 | -18.0 | -10.0 | -2.2 | 6.8 | 4.3 | 59.2 | 14.1 | -10.1 | 6.3 | -7.6 | 1.5 | +66.1% |
| 2008 | -1.6 | 48.3 | 104.5 | -19.2 | 17.0 | -3.5 | -11.0 | -12.0 | -38.5 | 0.0 | -17.5 | -27.3 | −21.3% |
| 2007 | 2.4 | -19.5 | -21.4 | 5.5 | 7.8 | -20.0 | 22.0 | -13.9 | 0.0 | 14.3 | 49.2 | 70.4 | +79.4% |
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Buy / hold / sell counts